Search results
Showing 9031 to 9045 of 9052 results
Patients with rare blood disorders to receive new treatment option, says NICE
In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).
A 'safe space' for addressing complex health technology assessment challenges
Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
New life-changing treatment option recommended for type of rare epilepsy
This marks a significant step forward for around 1,400 people living with this rare and severe form of epilepsy, which typically begins in early childhood.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..
New tests could spare people with early breast cancer from unnecessary chemotherapy
More people with early breast cancer could be spared chemotherapy and therefore avoid the side effects associated with the treatment after tumour profiling tests were recommended by NICE.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
NICE conditionally recommends 5 promising technologies for Parkinson's disease
These promising technologies could help improve symptoms and quality of life for people with Parkinson’s disease.